Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Janssen's Novel Bispecific Antibodies TALVEY® (talquetamab) and TECVAYLI® (teclistamab) Shows Positive CHMP Opinions for Refractory Multiple Myeloma Treatment

Janssen has received positive opinions for two novel talquetamab and teclistamab bispecific antibodies for the trreatment of patients with Relapsed and Refractory Multiple Myeloma.

Talquetamab is a bispecific T-cell engaging antibody designed for the treatment of multiple myeloma. This antibody is engineered to bind to both CD3, which is present on T-cells, and GPRC5D, a protein that is highly expressed on multiple myeloma cells as well as on certain types of tissues.

Talquetamab is administered via subcutaneous injection and is under investigation in various clinical trials to assess its effectiveness and safety as a potential treatment for multiple myeloma.

On the other hand, Teclistamab represents a significant advancement in the realm of cancer treatment. As an off-the-shelf bispecific antibody, it offers a readily accessible therapeutic option for patients. Administered through subcutaneous injections, Teclistamab works by harnessing the power of two cellular targets, BCMA and CD3.

Multiple myeloma is indeed a complex and heterogeneous disease. Despite significant advancements in the treatment of multiple myeloma, it remains challenging to completely cure, and the disease's characteristics can vary widely among individuals.

Talquetamab, novel bispecific antibody is specifically designed to target GPRC5D, a protein that plays a significant role in the progression of multiple myeloma.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024